Utq Acquisition Corp, 919 N Market St, Ste 950, Wilmington, DE 19801, US

NRx Pharmaceuticals, Inc. is a pharmaceutical company based in Wilmington, DE that focuses on developing breakthrough medicines for individuals suffering from life-threatening conditions such as bipolar depression, post-traumatic stress disorder (PTSD), chronic pain, and suicidal ideation. Their lead candidate, NRX-101, is the first oral medication currently undergoing FDA trials for suicidal bipolar depression, offering hope to those in need of effective treatment options. With a strong emphasis on scientific research and clinical approach, NRx Pharmaceuticals aims to address the urgent need for non-addictive and non-sedating pain medication in light of the ongoing opioid crisis. Their commitment to innovation and development is evident through their collaborations with Lotus Pharmaceuticals and Alvogen Inc. to commercialize NRX-101, as well as their FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for the treatment of complicated urinary tract infections and pyelonephritis.Generated from the website

Snapnsure Insurance Service

Klehr Harrison Harvey

Keystate Corporate Management

Accuracy Consulting